erthang,it's a real possibility
After extensive due diligence,last year Abbott Laboratories signed an agreement for semi-exclusive rights to commercialize products using BioCurex technology. This is validation that the company is past the point of “scientific risk.” Abbot does not make an investment in a company unless it has carried out substantial technical due diligence and intends to reap hundreds of millions of dollars.
One market for BioCurex technology (testing for several types of cancers, including lung and breast) is estimated at up to $2 billion annually. One example of a portion of that market is PSA (Prostate-Specific Antigen) testing, estimated at $450 million. Tests also indicate RECAF can be used for screening Pap smears for cervical cancer. In North America, this represents a market of over $1 billion. If BioCurex’s technology is added to the Pap test, then revenue from Pap smears alone could reach ten million dollars.
Tests show BioCurex technology successfully detects more than 90% of all cancers in blood or tissue samples, significantly better than any present method.
Once revenues start coming in the company will be self-sustaining. It won’t have to look for outside money to complete the rest of its platform technology.
